News >

Expert Discusses Developments in ALK/ROS1-Positive NSCLC

Danielle Bucco
Published: Tuesday, Dec 05, 2017

Vincent K. Lam, MD

Vincent K. Lam, MD
In a recent phase II study, the next-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) lorlatinib induced an objective response rate (ORR) of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer (NSCLC).

-translocated NSCLC.

OncLive: Please provide an overview of your presentation.

Lam: I discussed the latest developments for patients with ALK- and ROS1-positive NSCLC. We are seeing that treatment development is much better with the ALK-targeted therapies compared with ROS1. Overall, it is an exciting time. 

What potential is there with entrectinib as a treatment for patients with ROS1-positive NSCLC?

ROS1 falls behind compared with ALK development. It is important to keep in mind that not all ALK inhibitors work for ROS1-positive NSCLC, such as alectinib. In terms of the ROS1 data, the furthest along is lorlatinib. The phase II trial in the ROS1 cohort showed good response for patients who have been previously treated or are treatment naïve. These results are similar to what we are seeing with ALK.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication